GHRP-6: What It Is and How the Ghrelin-Mimic Peptide Works

At a glance

What is GHRP-6?

GHRP-6 is a synthetic six–amino acid peptide and one of the first growth hormone-releasing peptides developed. It is sold through wellness and "research peptide" channels and promoted for muscle gain, recovery, and appetite stimulation. It was never marketed as an approved drug.

How does it work?

GHRP-6 activates the growth hormone secretagogue receptor (the ghrelin receptor), prompting the pituitary to release growth hormone, and it is proposed to act partly by blunting the body's growth-hormone "brake," somatostatin. Compared with newer peptides it is less selective, notably:

• Increasing appetite
• Modestly raising cortisol
• Modestly raising prolactin

Laboratory work also describes growth hormone secretagogue receptors in heart and blood-vessel tissue, which is the basis for preclinical interest in other effects. The marketed benefits are extrapolated from the growth hormone rise. This describes the proposed mechanism, separate from proven outcomes.

Is it FDA-approved?

No. GHRP-6 is not approved by the FDA and has no approved product. It has been treated as not eligible for routine 503A compounding in the U.S. and is not approved for performance or anti-aging. In sport, growth hormone-releasing peptides including GHRP-6 are prohibited at all times under the WADA list.

What does the research show?

The human evidence is short pharmacology. According to PubMed, an infusion study in healthy men found GHRP-6 raised growth hormone and IGF-1 while the pituitary remained responsive, a hormone-level result rather than a clinical outcome. Cardiovascular and cell-protective effects are described mainly in preclinical work and reviews. No controlled human trials support the marketed muscle, fat, recovery, or anti-aging uses.

Evidence strength

Low research: Human data are limited to short studies of growth hormone release, with the marketed wellness benefits resting on animal and laboratory work.

Sources: a growth hormone pharmacology study (Jaffe et al., Journal of Clinical Endocrinology & Metabolism, 1993, DOI: 10.1210/jcem.77.6.7903313) and a review of growth hormone secretagogues (Cao et al., Trends in Endocrinology & Metabolism, 2005, DOI: 10.1016/j.tem.2005.11.004), both indexed on PubMed; and the WADA Prohibited List. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.